MSD is expected to introduce another oncology pipeline to Korea.

According to industry sources, MSD Korea has submitted an application for the approval of its oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, ‘Welireg (belzutifan),’ to the Ministry of Food and Drug Safety.

The drug had been designated as an orphan drug in January for the treatment of Von Hippel-Lindau disease.

The indication the company applied in Korea is also for the treatment of adult patients with VHL disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surg